Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort.
Epidemiology and Burden of Atopic Dermatitis Involving the Head, Neck, Face, and Hand: a Cross Sectional Study from the TARGET-DERM AD Cohort (RAD 2021)
Challenge
This is the RAD 2021 poster—the earliest presentation—of the head, neck, face, and hand AD burden findings that were subsequently published in manuscript form (Row 10) and presented at Fall Clinical 2022 (Row 35). First dissemination of the finding that difficult-to-treat site involvement affects 85% of moderate-to-severe AD patients.
Solution
TARGET-DERM AD cohort cross-sectional analysis of difficult-to-treat AD site prevalence and HRQoL impact (POEM, DLQI/CDLQI) at RAD 2021.
Impact
Initial conference dissemination of the difficult-to-treat site burden data at RAD 2021 established the evidence foundation for subsequent manuscript publication and multi-venue dissemination, directly informing AbbVie's body-site-specific label development strategy for AD therapies.
